Is your patient still using rosiglitazone? by Gov-Ari, Hanna K. & Stevermer, James J.
282 THE JOURNAL OF FAMILY PRACTICE  |   MAY 2011  |   VOL 60, NO 5
Priority Updates from the Research Literature 
from the Family Physicians Inquiries Network
Hanna K. Gov-Ari, MD;
James J. Stevermer, MD, 
MSPH
Department of Family and 
Community Medicine,
University of Missouri-
Columbia
 P U R L s  E D I T O R
John Hickner, MD, MSc 
Cleveland Clinic
Is your patient still using 
rosiglitazone? 
Many doctors stopped prescribing rosiglitazone in 2007, 
when a study linked it to an elevated MI risk. An update 
to that study underscores the need to switch patients still 
taking it to another drug.  
PRACTICE CHANGER
Do not initiate rosiglitazone therapy for pa-
tients with diabetes, and consider switching 
those who are already taking it to pioglitazone.1 
STRENGTH OF RECOMMENDATION
A: Based on a meta-analysis of 56 random-
ized trials.
Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis 
of risk for myocardial infarction and cardiovascular mortality. Arch 
Intern Med. 2010;170:1191-1201. 
ILLUSTRATIVE CASE
A 60-year-old African American man with 
type 2 diabetes comes in for a follow-up visit. 
He is currently taking metformin 1000 mg BID, 
glipizide 10 mg BID, and rosiglitazone 8 mg 
daily. His glucose levels are well controlled 
and his last hemoglobin A1c was 6.8%.
Should you discontinue the rosiglitazone?
We have been reluctant to use rosi-glitazone for the treatment of type 2 diabetes since 2007, when 
a meta-analysis found the drug to be asso-
ciated with a signifi cant elevation in risk for 
myocardial infarction (MI) and a borderline 
signifi cant increase in risk for cardiovascular 
mortality.2 A US Food and Drug Administra-
tion (FDA) advisory committee reviewed the 
evidence in 2007, but did not recommend 
removing rosiglitazone (Avandia, manufac-
tured by GlaxoSmithKline [GSK]) from the 
market.3  Annual US sales of the drug, which 
fell by more than 60% over the next 2 years, 
totaled $408 million in 2009.4 
Body of evidence grows 
Since then, additional evidence of the risk as-
sociated with rosiglitazone has come to light. 
Th e latest study, reviewed here, is an update 
of the 2007 meta-analysis.2  Th e authors used 
standard methodology like that of their origi-
nal study, and added an alternative meth-
odology that enabled them to include more 
trials.
Two FDA safety advisories have also 
been issued. Th e fi rst, in September 2010, 
notifi ed providers and patients of plans to 
restrict access to rosiglitazone because of its 
elevated risk of cardiovascular events. An up-
date followed in February 2011, indicating 
that the drug label now includes a black box 
warning of that risk.5  
STUDY SUMMARY
Expanded meta-analysis 
highlights MI risk 
Th e new meta-analysis included 56 trials and 
a total of 35,531 patients. Of these, 19,509 
(55%) were randomized to receive rosigli-
tazone, and 16,022 (45%) were assigned to a 
comparator group, which could be either pla-
cebo or active treatment. 
To be included in the meta-analysis, a 
trial had to have a randomized comparator 
group, the duration of treatment had to be 
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similar for all study groups, and participants 
had to have >24 weeks of drug exposure.1 Out-
comes of interest were MI and cardiovascular 
mortality. Th e earlier meta-analysis included 
42 studies, all of which had at least one of 
these outcomes.2 Th e alternative methodolo-
gy used in this study—in which smaller stud-
ies were grouped by randomization ratios 
and larger trials were reviewed individually—
made it possible to include studies without 
any MIs or cardiovascular deaths. 
Th e researchers identifi ed 3 groups of tri-
als for inclusion: 
•   Th e fi rst group consisted of 5 studies 
that GSK submitted to the FDA in 1999 
for presentation to the advisory com-
mittee, which recommended approval 
of rosiglitazone. In these 5 trials, 1967 
patients were randomly assigned to 
receive rosiglitazone and 793 patients 
received either a comparator drug or 
placebo.
•   Th e second group included 48 trials, 
which were primarily identifi ed from 
the GSK clinical trial registry. Th ese 
trials were not originally published, 
but a legal court settlement mandated 
their eventual publication,6  providing 
new data not available for the previ-
ous meta-analysis.  In these 48 trials, a 
total of 11,231 patients were randomly 
assigned to receive rosiglitazone and 
7473 received either a comparator 
drug or placebo. 
•   Th e third—and smallest—group fea-
tured 3 large prospective randomized 
trials that had been published in ma-
jor medical journals.7-9 A total of 6311 
patients were randomly assigned to 
receive rosiglitazone and 7756 patients 
received comparator drugs. 
❚ Fifteen of the 56 trials did not report 
any MIs, and 30 trials did not report any car-
diovascular mortality. Th e trials without ei-
ther outcome were not part of the primary 
analysis, but were included in the alternative 
analysis. 
❚ For the 41 trials with ≥1 MI, rosi-
glitazone therapy signifi cantly increased the 
risk of MI (odds ratio [OR], 1.28; 95% confi -
dence interval [CI], 1.02-1.63; P=.04),  but did 
not aff ect cardiovascular mortality (OR, 1.03; 
95% CI, 0.78-1.36; P=.04).
❚ The results of the alternative analysis
were very similar to the primary results, show-
ing an increased risk for MI (OR, 1.28; 95% CI, 
1.01-1.62), but no change in cardiovascular 
mortality (OR, 0.99; 95% CI, 0.75-1.32). 
WHAT’S NEW?
A stronger case 
for a safer alternative
We believe that this meta-analysis strength-
ens the case against the use of rosiglitazone 
for the treatment of type 2 diabetes. Th e num-
ber of trials and patients studied is substan-
tial, and the alternative analytic approach 
allowed the researchers to include all 56 
available trials, whether or not any MIs or car-
diovascular deaths were reported. 
At an FDA advisory committee meeting 
in July 2010, the recommendation to remove 
rosiglitazone from the market received a plu-
rality of votes.  Th at recommendation was 
not carried out, however because 4 other 
options—all of which involved leaving rosi-
glitazone on the market—taken together, re-
ceived more votes.10
We think this meta-analysis provides 
substantial doubt about the safety of rosi-
glitazone. If there is a safer alternative, the 
decision not to use rosiglitazone becomes 
even easier.  An important question, then, is 
whether the other thiazolidinedione on the 
market, pioglitazone (Actos), carries similar 
risks. 
Th e PROACTIVE trial, a large cardiovas-
cular outcomes study published in 2005,11
and a patient-level meta-analysis of cardio-
vascular outcomes published in 2007,12 as-
sessed the risk of death, MI, and stroke in a 
diverse population of patients taking piogli-
tazone. Compared with studies of cardiovas-
cular events associated with rosiglitazone, 
the PROACTIVE trial and the meta-analysis 
showed that pioglitazone has a signifi cantly 
lower risk of death, MI, or stroke.  
For patients who are doing well on rosi-
glitazone, a within-class switch to piogli-
tazone would appear to decrease coronary 
artery events. However, it must be noted that 
both drugs have a black box warning regard-
ing congestive heart failure. (Th e black box 
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warning for rosiglitazone now identifi es the 
increased risk of MI, as well).5 
CAVEATS
Missing data weaken analysis
Th e authors of the meta-analysis reported 
here were unable to obtain individual patient 
outcomes, which would have allowed them 
to do a more powerful analysis. However, 
other meta-analyses, including one from the 
FDA,13 found similar results.
CHALLENGES TO IMPLEMENTATION
Patients and physicians may be 
reluctant to switch 
Th eoretically, a switch to pioglitazone is an 
easy choice, as it is the same class of medi-
cation as rosiglitazone but has a lower risk 
of MI. Th e use of rosiglitazone caused about 
83,000 excess MIs between 1999 and 2007, 
the FDA estimated.14 Th at number has since 
been downgraded to up to 6000 excess MIs 
annually to refl ect the reduced usage of the 
drug.1,14 But when patients are doing well 
on a particular medication, neither they nor 
their doctor may want to change to another 
drug, especially when the adverse eff ects 
of the current medication are uncommon. 
Nonetheless, reevaluation of their diabetic 
medication regimen often gives patients an 
opportunity to ensure that they are taking 
the best fi rst-line agent—which in many cas-
es is metformin, and not a thiazolidinedione 
at all.15                                                  JFP
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